Top Scripps scientist and biotech co-founder makes an abrupt — and unexplained — exit
The scientific founder at the newly public biotech Synthorx has abruptly left La Jolla’s prestigious Scripps Research. But we don’t know why.
The San Diego Union-Tribune reported that star scientist Floyd Romesberg departed in mid-June after he had been cleared of a Title IX investigation regarding possible sexual discrimination. Scripps told the local newspaper that they had conducted a thorough investigation and found no wrongdoing.
But they refused to say why he left.
Romesberg provided the scientific expertise for Synthorx, which scored a $150 million IPO 7 months ago. Like Nektar, Synthorx started out with the knowledge that Proleukin never lived up to its incredible initial promise in cancer, largely because of a bad tox profile highlighted by vascular leak syndrome. And the little biotech has been working on its own alternative under the guidance of CEO Laura Shawver, an experienced biotech vet.
His lab at Scripps has been working “to improve on evolution through the expansion of the genetic alphabet, and to develop novel antibiotics and aptamers.”